Ticker Details
CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
IPO Date:	October 19, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.86B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.61 | 2.80%
Avg Daily Range (30 D):	$1.30 | 2.44%
Avg Daily Range (90 D):	$1.42 | 2.69%

Institutional Daily Volume
Avg Daily Volume:	1.21M
Avg Daily Volume (30 D):	1.57M
Avg Daily Volume (90 D):	1.65M

Trade Size
Avg Trade Size (Sh.):	62
Avg Trade Size (Sh.) (30 D):	49
Avg Trade Size (Sh.) (90 D):	51

Institutional Trades
Total Institutional Trades:	6,542
Avg Institutional Trade:	$2.95M
Avg Institutional Trade (30 D):	$2.65M
Avg Institutional Trade (90 D):	$2.61M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.7M
Avg Closing Trade (30 D):	$7.57M
Avg Closing Trade (90 D):	$8.09M
Avg Closing Volume:	91.01K

News

May 26, 2026 @ 12:35 AM Better Gene-Editing Stock: CRISPR Therapeutics or ... Source: Prosper Junior Bakiny

May 11, 2026 @ 8:15 PM 1 Top Wall Street Analyst Thinks CRISPR Therapeuti... Source: Prosper Junior Bakiny

May 6, 2026 @ 7:30 AM Is This Millionaire-Maker Biotech Stock a Buy Righ... Source: Prosper Junior Bakiny

Apr 30, 2026 @ 10:10 AM Want to Build Real Wealth in Healthcare? These Sto... Source: Adria Cimino

Apr 30, 2026 @ 9:10 AM What's the Next Big Thing After GLP-1 Drugs? CRISP... Source: Adria Cimino

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-6.2	$-1.28	$-1.35
Diluted EPS	$-6.2	$-1.28	$-1.35
Revenue	$4.1M	$1.46M	$.86M
Gross Profit
Net Income / Loss	$-568.53M	$-122.93M	$-130.61M
Operating Income / Loss	$-646.4M	$-130.25M	$-154.76M
Cost of Revenue
Net Cash Flow	$184.59M	$72.27M	$61.06M
PE Ratio